Effect and mechanism analysis of siRNA in inhibiting VEGF and its anti-angiogenesis effects in human osteosarcoma bearing rats.

OBJECTIVE To explore the effect of siRNA in inhibiting vascular endothelial growth factor (VEGF) expression in tumor cells from human osteosarcoma bearing rats and its anti-angiogenesis effect, to further study the reliability, effectiveness and safety of VEGF as a therapeutic target in treating osteosarcoma. MATERIALS AND METHODS After treatment, the long diameter and short diameter of tumor lesion were detected by Vernier caliper, and the tumor volume and tumor inhibition rate were calculated. The whole-body fluorescence imaging was used to detect the general morphology and volume change of tumor lesion before and after treatment. The rats were killed after treatment, RT-PCR and Western blot were used to detect VEGF expression. MTT was used to detect the proliferative ability of tumor cells in vitro. RESULTS Three chemotherapies could inhibit the growth of tumor lesion, the decrease of tumor volume was significant (p < 0.05), the therapeutic effect in Ad-VEGF-siRNA + neoadjuvant chemotherapy group was better than the other two groups, the differences were statistically significant (p < 0.05). Furthermore, the three chemotherapies could inhibit the invasiveness of tumor cells, which was most significant in Ad-VEGF-siRNA + neoadjuvant chemotherapy group (p < 0.05). CONCLUSIONS The growth of tumor tissue in osteosarcoma bearing rats is inhibited in Ad-VEGF-siRNA group, Ad-VEGF-siRNA + neoadjuvant chemotherapy group and Ad-VEGF-siRNA + anti-angiogenesis chemotherapy group. The effect in Ad-VEGF-siRNA + neoadjuvant chemotherapy is more significant than simple biological therapy or Ad-VEGF-siRNA + anti-angiogenesis chemotherapy.

[1]  Y. Tsuboi,et al.  Treatment with mild brain hypothermia for cardiopulmonary resuscitation after myoclonic seizures in infant with robertsonian type of trisomy 13. , 2015, European review for medical and pharmacological sciences.

[2]  J. Brieger,et al.  Angiogenesis-related prognosis in patients with oral squamous cell carcinoma-role of the VEGF +936 C/T polymorphism. , 2015, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[3]  M. Hillenbrand,et al.  Vascular endothelial growth factor gene therapy improves nerve regeneration in a model of obstetric brachial plexus palsy , 2015, Neurological research.

[4]  Y. Akao,et al.  Colorectal cancer cell-derived microvesicles containing microRNA-1246 promote angiogenesis by activating Smad 1/5/8 signaling elicited by PML down-regulation in endothelial cells. , 2014, Biochimica et biophysica acta.

[5]  K. Horwitz,et al.  Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling , 2014, BMC Cancer.

[6]  Kazuhiro Takahashi,et al.  The Wilms' Tumor Gene WT1 − 17AA/− KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model , 2014, Translational oncology.

[7]  Masao Iwata,et al.  Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models , 2014, Journal of thyroid research.

[8]  M. Bouvet,et al.  Osteosarcoma Cells Enhance Angiogenesis Visualized by Color‐Coded Imaging in the In Vivo Gelfoam® Assay , 2014, Journal of cellular biochemistry.

[9]  V. Tapia,et al.  Role of nerve growth factor and its TRKA receptor in normal ovarian and epithelial ovarian cancer angiogenesis , 2014, Journal of Ovarian Research.

[10]  T. Mikkelsen,et al.  Mechanisms of Glioma Formation: Iterative Perivascular Glioma Growth and Invasion Leads to Tumor Progression, VEGF-Independent Vascularization, and Resistance to Antiangiogenic Therapy12 , 2014, Neoplasia.

[11]  T. Das,et al.  Capsaicin-Induced Activation of p53-SMAR1 Auto-Regulatory Loop Down-Regulates VEGF in Non-Small Cell Lung Cancer to Restrain Angiogenesis , 2014, PloS one.

[12]  S. W. Kim,et al.  Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[13]  S. Rho,et al.  Thioridazine inhibits angiogenesis and tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian cancer xenografts , 2014, Oncotarget.

[14]  Tomoko Kayashima,et al.  Cecal succinate elevated by some dietary polyphenols may inhibit colon cancer cell proliferation and angiogenesis. , 2014, Journal of agricultural and food chemistry.

[15]  N. Jonjić,et al.  Plasma Levels of Osteopontin and Vascular Endothelial Growth Factor in Association with Clinical Features and Parameters of Tumor Burden in Patients with Multiple Myeloma , 2014, BioMed research international.

[16]  J. Bidwell,et al.  Haplotype analysis on chromosome 6p of tumor necrosis factor alpha, vascular endothelial growth factor A, and interleukin-17F alleles associated with corneal transplant rejection. , 2014, Transplantation proceedings.

[17]  L. Miele,et al.  Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells , 2014, Vascular cell.

[18]  D. Ingber,et al.  Paxillin controls endothelial cell migration and tumor angiogenesis by altering neuropilin 2 expression , 2014, Journal of Cell Science.

[19]  Sabita Roy,et al.  Morphine inhibits migration of tumor-infiltrating leukocytes and suppresses angiogenesis associated with tumor growth in mice. , 2014, The American journal of pathology.

[20]  M. Isobe,et al.  Tumor associated osteoclast-like giant cells promote tumor growth and lymphangiogenesis by secreting vascular endothelial growth factor-C. , 2014, Biochemical and biophysical research communications.

[21]  Dong Wang,et al.  Apurinic/apyrimidinic endonuclease 1 induced upregulation of fibroblast growth factor 2 and its receptor 3 induces angiogenesis in human osteosarcoma cells , 2014, Cancer science.

[22]  V. Herrera,et al.  DEspR Roles in Tumor Vasculo-Angiogenesis, Invasiveness, CSC-Survival and Anoikis Resistance: A ‘Common Receptor Coordinator’ Paradigm , 2014, PloS one.

[23]  V. Rohde,et al.  Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors , 2014, Neurosurgical Review.

[24]  R. Milewski,et al.  Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients. , 2013, Advances in medical sciences.

[25]  M. Harada‐Shiba,et al.  Therapy with siRNA for Vegf-c but not for Vegf-d suppresses wide-spectrum organ metastasis in an immunocompetent xenograft model of metastatic mammary cancer. , 2013, Anticancer research.

[26]  G. Breier,et al.  PHD4 Stimulates Tumor Angiogenesis in Osteosarcoma Cells via TGF-α , 2013, Molecular Cancer Research.

[27]  Ping Chen,et al.  Clinical significance of survivin and VEGF mRNA detection in the cell fraction of the peripheral blood in non-small cell lung cancer patients before and after surgery. , 2013, Lung cancer.

[28]  C. Teng,et al.  TUMORIGENESIS AND NEOPLASTIC PROGRESSION Activated PAR-2 Regulates Pancreatic Cancer Progression through ILK / HIF-a e Induced TGF-a Expression and MEK / VEGF-A e Mediated Angiogenesis , 2013 .

[29]  A. Bogers,et al.  DNA Microarray and Quantitative Analysis Reveal Enhanced Myocardial VEGF Expression with Stunted Angiogenesis in Human Tetralogy of Fallot , 2013, Cell Biochemistry and Biophysics.

[30]  H. Lenz,et al.  Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab , 2013, PloS one.

[31]  C. Bloomfield,et al.  A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance) , 2013, Investigational New Drugs.

[32]  L. Wang,et al.  Relaxin promotes in vitro tumour growth, invasion and angiogenesis of human Saos-2 osteosarcoma cells by AKT/VEGF pathway. , 2013, European review for medical and pharmacological sciences.

[33]  Jinghong Xu,et al.  miRNA-27b Targets Vascular Endothelial Growth Factor C to Inhibit Tumor Progression and Angiogenesis in Colorectal Cancer , 2013, PloS one.

[34]  C. Napoli,et al.  Osteosarcoma cells induce endothelial cell proliferation during neo‐angiogenesis , 2013, Journal of cellular physiology.

[35]  L. Bergmann,et al.  Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study , 2013, Oncology Research and Treatment.

[36]  S. Grajek,et al.  Prognostic usefulness of IL-6 and VEGF for the occurrence of changes in coronary arteries of patients with stable angina and implanted stents. , 2014, European review for medical and pharmacological sciences.

[37]  Peng Cao,et al.  Original Article HOXA9 regulates angiogenesis in human hypertrophic scars: induction of VEGF secretion by epidermal stem cells , 2014 .

[38]  I. Khoroshilov.  [Patients before and after surgery: starvation or adequate nutrition]. , 2002, Vestnik khirurgii imeni I. I. Grekova.